melphalan pharmexon 50 mg
emcure pharma uk limited - marea britanie - melphalanum - pulb. si solv. pt. sol. inj./perf. - 50mg - agenti alchilanti analogi de nitrogen mustard
melfalan amring 50 mg
drehm pharma gmbh - austria - melphalanum - pulb.+solv. pt. sol. inj./perf. - 50mg - agenti alchilanti analogi de nitrogen mustard
melfalan tillomed 50 mg
tillomed pharma gmbh - germania - melphalanum - pulb. si solv. pt. sol. inj./perf. - 50mg - agenti alchilanti analogi de nitrogen mustard
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - sânii neoplasme - agenți antineoplazici - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
pazopanib adalvo 200 mg
alvogen malta (out-licensing) ltd./amol ltd. - malta - pazopanib - compr. film. - 200mg - inhibitori de protein-kinaza
gavreto
roche registration gmbh - pralsetinib - carcinom, pulmonar non-celulă mică - agenți antineoplazici - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
melfalan zentiva 50 mg
mias pharma limited - irlanda - melphalanum - pulb. si solv. pt. sol. inj./perf. - 50mg - agenti alchilanti analogi de nitrogen mustard
pazopanib zentiva 200 mg
remedica ltd - cipru - pazopanibum - compr. film. - 200mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
pazopanib zentiva 400 mg
remedica ltd - cipru - pazopanibum - compr. film. - 400mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza
pyzypi 200 mg
remedica ltd - cipru - pazopanibum - compr. film. - 200mg - inhibitori de protein-kinaza alti inhibitori de protein kinaza